Healthcare resource use and costs of managing children and adults with lysosomal acid lipase deficiency at a tertiary referral centre in the United Kingdom

Show simple item record

dc.contributor.author Guest, Julian F.
dc.contributor.author Ingram, Andy
dc.contributor.author Ayoub, Nadia
dc.contributor.author Hendriksz, Christian J.
dc.contributor.author Murphy, Elaine
dc.contributor.author Rahman, Yusof
dc.contributor.author McKiernan, Patrick
dc.contributor.author Mundy, Helen
dc.contributor.author Deegan, Patrick
dc.date.accessioned 2018-03-28T07:36:15Z
dc.date.available 2018-03-28T07:36:15Z
dc.date.issued 2018-02-02
dc.description.abstract OBJECTIVE : To estimate clinical progression and resource utilisation together with the associated costs of managing children and adults with LAL Deficiency, at a tertiary referral centre in the UK. METHODS : A retrospective chart review was undertaken of patients in the UK with a confirmed diagnosis of LAL Deficiency who were managed at a LAL Deficiency tertiary referral treatment centre. Patients' pathways, treatment patterns, health outcomes and resource use were quantified over differing lengths of time for each patient enabling the NHS cost of patient management in tertiary care to be estimated. RESULTS : The study population comprised 19 patients of whom 58% were male. Mean age at the time of initial presentation was 15.5 years and the mean age at diagnosis was 18.0 years. 63%, 53% and 42% of patients had hepatomegaly, abnormal lipid storage and splenomegaly at a mean age of presentation of 17.8, 17.1 and 20.9 years, respectively. Over a period of 50 years there were a mean of 48.5 clinician visits and 3.4 hospital admissions per patient. The mean NHS cost of patient management at a LAL Deficiency tertiary referral treatment centre, spanning a period of over 50 years was £61,454 per patient. CONCLUSION : This study provides important insights into a number of aspects of the disease that are difficult to ascertain from published case reports. Additionally, it provides the best estimate available of NHS resource use and costs with which to inform policy and budgetary decisions pertaining to managing this ultra-orphan disease. en_ZA
dc.description.department Paediatrics and Child Health en_ZA
dc.description.librarian am2018 en_ZA
dc.description.sponsorship Synageva Biopharma Corp, Lexington, MA, US, now part of Alexion Pharmaceuticals Inc., Cheshire, CT, US. en_ZA
dc.description.uri http://www.plosone.org en_ZA
dc.identifier.citation Guest JF, Ingram A, Ayoub N, Hendriksz CJ, Murphy E, Rahman Y, et al. (2018) Healthcare resource use and costs of managing children and adults with lysosomal acid lipase deficiency at a tertiary referral centre in the United Kingdom. PLoS ONE 13(2): e0191945. https://DOI.org/ 10.1371/journal.pone.0191945. en_ZA
dc.identifier.issn 1932-6203 (online)
dc.identifier.other 10.1371/journal.pone.0191945
dc.identifier.uri http://hdl.handle.net/2263/64320
dc.language.iso en en_ZA
dc.publisher Public Library of Science en_ZA
dc.rights © 2018 Guest et al. This is an open access article distributed under the terms of the Creative Commons Attribution License. en_ZA
dc.subject Lipoprotein en_ZA
dc.subject Low density en_ZA
dc.subject Lysosomal acid lipase (LAL) en_ZA
dc.subject National health service (NHS) en_ZA
dc.subject United Kingdom (UK) en_ZA
dc.subject Alanine aminotransferase en_ZA
dc.subject Aspartate aminotransferase en_ZA
dc.subject Bilirubin en_ZA
dc.subject Gamma-glutamyl transferase en_ZA
dc.subject Splenomegaly en_ZA
dc.subject Prescription en_ZA
dc.subject Patient care en_ZA
dc.subject Liver transplant en_ZA
dc.subject Hospital admissions en_ZA
dc.subject Hepatomegaly en_ZA
dc.subject Health care utilization en_ZA
dc.subject Health care cost en_ZA
dc.title Healthcare resource use and costs of managing children and adults with lysosomal acid lipase deficiency at a tertiary referral centre in the United Kingdom en_ZA
dc.type Article en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record